These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765 [TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641 [TBL] [Abstract][Full Text] [Related]
5. The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? Hong JC; Salama JK Cancer Treat Rev; 2017 Jan; 52():22-32. PubMed ID: 27886588 [TBL] [Abstract][Full Text] [Related]
6. The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma. Cheung P; Thibault I; Bjarnason GA Curr Opin Support Palliat Care; 2014 Sep; 8(3):258-64. PubMed ID: 25090288 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy for oligometastatic disease. Hanna GG; Landau D Clin Oncol (R Coll Radiol); 2015 May; 27(5):290-7. PubMed ID: 25770653 [TBL] [Abstract][Full Text] [Related]
8. New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Ricardi U; Filippi AR; Franco P Expert Rev Anticancer Ther; 2013 Oct; 13(10):1145-55. PubMed ID: 24134418 [TBL] [Abstract][Full Text] [Related]
9. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760 [TBL] [Abstract][Full Text] [Related]
10. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Saluja R; Cheung P; Zukotynski K; Emmenegger U Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982 [TBL] [Abstract][Full Text] [Related]
11. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol. Palma DA; Giuliani ME; Correa RJM; Schneiders FL; Harrow S; Guckenberger M; Zhang T; Bahig H; Senthi S; Chung P; Olson R; Lock M; Raman S; Bauman GS; Lok BH; Laba JM; Glicksman RM; Nguyen TK; Lang P; Helou J; Goodman CD; Mendez LC; van Rossum PSN; Warner A; Gaede S; Allan AL BMC Palliat Care; 2024 Sep; 23(1):223. PubMed ID: 39244532 [TBL] [Abstract][Full Text] [Related]
12. The evolving role of radiotherapy in treatment of oligometastatic NSCLC. Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370 [TBL] [Abstract][Full Text] [Related]
13. [Stereotactic body radiation therapy and oligometastases]. Bourgier C; Azria D; Fenoglietto P; Riou O; Almaghrabi MY; Supiot S; Mornex F; Giraud P Cancer Radiother; 2014; 18(4):337-41. PubMed ID: 24792996 [TBL] [Abstract][Full Text] [Related]
14. Radiation in the Treatment of Oligometastatic and Oligoprogressive Disease: Rationale, Recent Data, and Research Questions. Zayed S; Correa RJM; Palma DA Cancer J; 2020; 26(2):156-165. PubMed ID: 32205541 [TBL] [Abstract][Full Text] [Related]
17. Adrenal oligometastasis cured with stereotactic ablative radiotherapy. Malone J; Pantarotto JR; Tiberi D; Malone S Radiol Case Rep; 2020 Nov; 15(11):2266-2270. PubMed ID: 32983297 [TBL] [Abstract][Full Text] [Related]
18. Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases. Conde-Moreno AJ; Lopez-Guerra JL; Macias VA; Vázquez de la Torre ML; Samper Ots P; San José-Maderuelo S; Pastor Peidro J; López-Torrecilla J; Expósito-Hernández J Clin Transl Oncol; 2016 Apr; 18(4):342-51. PubMed ID: 26329294 [TBL] [Abstract][Full Text] [Related]
19. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. Westover KD; Iyengar P; Sharma AN; Timmerman R Lung Cancer; 2015 Aug; 89(2):87-93. PubMed ID: 26028304 [TBL] [Abstract][Full Text] [Related]
20. Oligometastases: history of a hypothesis. Milano MT; Biswas T; Simone CB; Lo SS Ann Palliat Med; 2021 May; 10(5):5923-5930. PubMed ID: 32279519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]